As we continue to adjust to life with COVID-19 in our midst, each of us has had a unique experience regarding this virus. Here are some interesting options to consider for those that have either not yet received the vaccination or have not yet had COVID-19.
COVID-19 Protection & Treatment
CLL patients who have not had COVID-19 and have not received the vaccine may consider participating in a clinical trial studying the use of a prophylactic drug to avoid contracting the disease. It is hoped that this drug will offer six months or more of passive immunity. Read hereto learn about the Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adults.
For those who are within 10 days of testing positive for COVID-19, there is a treatment available that has been proven to decrease the risk of severe disease in high-risk patients. But it is not available everywhere, so you will need to do some planning in advance to know where to get it should the time come. Fortunately, the NIH publishes a list of locations where it is available. Read here to learn how monoclonal antibodies (mAb) work against the spike protein of SARS-CoV-2 that causes COVID-19, as well as how you may be able to lessen your symptoms should you test positive for COVID-19 infection.
During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner. Learn more here.
MRD Testing Update
Testing for Measurable (Minimal) Residual Disease (MRD) in CLL down to one in one million cells just got easier! Learn more here.
Join us on Friday, March 26th (11:00 AM PT, 12:00 PM MT, 1:00 PM CT, and 2:00 PM ET) for CLL Society’s COVID-19 Virtual Community Meeting: Contagion, Variants, and Vaccines as CLL experts Drs. Steve Rosen and Alexey Danilov, infectious disease physician Dr. Sanjeet Dadwal, lab scientist Dr. Susan Leclair, and CLL Society’s own Dr. Brian Koffman bring you the most up-to-date COVID-19 information and answer audience questions. Register here and submit your questions!
CAR-T Ed Forum: The Basic Science and Latest Data
Please join CLL Society for a two-hour event on Wednesday, April 21st (10:00 AM PT, 11:00 AM MT, 12:00 PM CT, and 1:00 PM ET) as we continue to strengthen your learning about CAR-T therapy. Dr. John Pagel will define CAR-T, explain how it works, and share where this treatment might be headed in the future. Dr. Tanya Siddiqi’s ongoing CAR-T clinical trial at the City of Hope National Medical Center is well known. She will be on-hand to present her most current data showing the success of CAR-T therapy in CLL, both with and without ibrutinib. Dr. Larry & Sharon Saltzman will share their CLL CAR-T journey from both the doctor-turned-patient perspective and the caregiver point of view. Learn more and register here!
Financial Aid from PAN Foundation
The PAN Foundation helps federally and commercially insured people living with life-threatening, chronic, and rare diseases with out-of-pocket costs for their prescribed medications. PAN’s chronic lymphocytic leukemia (CLL) patient assistance fund can provide up to $8,700 per year in financial assistance to pay for the deductibles, co-pays, and coinsurance costs associated with CLL treatment. Funds are available for CLL patients. Registration and additional information can be found here.
CLL Society Audience Survey
CLL Society believes strongly in equal access to quality education, support, and care. Our goal is to provide valuable resources and a supportive community to all CLL patients and caregivers during their journey. We have put together a brief survey in collaboration with graduate students from Indiana University to find out more about your experience with CLL Society. We value your feedback and would be grateful if you would complete the survey, here.
Please Support CLL Society
CLL Society is the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.